• Home
  • Our Pipeline
  • About Us
  • Science
    • Active Immunotherapies
    • GlyMab®
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), 8-12 November 2022 in Boston, MA, USA

by admin | Nov 6, 2022 | Moditope, Vaccines

V Brentville, P Symonds, J Chua, A Skinner, I Daniels, K Cook, S Koncarevic, R Martinez-Pinna, S Shah, RH Choudhury, P Bilimoria1, D Weston, A Al-Omari, J Davis and L Durrant

Vaccine Can Induce CD4-Mediated Responses to Homocitrullinated Peptides via Multiple HLA-Types and Confer Anti-Tumor Immunity

by admin | Apr 12, 2022 | Moditope, Vaccines

Katherine Cook, Wei Xue, Suha Atabani, Peter Symonds, Abdullah Al Omari, Ian Daniels, Sabaria Shah, Ruhul Hasan Choudhury, Daisy Weston, Rachael Metheringham, Victoria Brentville and Lindy Durrant ABSTRACT: Homocitrullination is the post translation modification (PTM)...

PAD-2- mediated citrullination of nucleophosmin provides an effective target for tumor immunotherapy

by admin | Feb 14, 2022 | Moditope, Vaccines

Ruhul H Choudhury, Peter Symonds, Samantha J Paston, Ian Daniels, Katherine W Cook, Mohamed Gijon, Rachael L Metheringham, Victoria A Brentville, Lindy G Durrant ABSTRACT:Background The enzymatic conversion of arginine to citrulline is involved in gene and protein...
Next Entries »

Recent Posts

  • Scancell Receives FDA Fast Track Designation for iSCIB1+
  • Scancell announces CFO Transition
  • Edison Report – Redesigning immunity: The next frontier in immuno-oncology
  • Scancell Financial Year 2026 Interim Results
  • H126: solid iSCIB1+ data underpins planned progress

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy